Mont-Saint-Guibert, Belgium – April 26th 2026 – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the developmentand commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that, according to a nationally representative survey commissioned by Nyxoah and conducted by OnePoll (2025)*, millions of people across the UK could be living with undiagnosed sleep apnoea, as new research reveals that the condition is still widely misunderstood and too often dismissed as nothing more than snoring.
 
Sleep apnoea is a serious medical disorder in which breathing stops and starts during sleep, sometimes hundreds of times per night, preventing the body from reaching the deeper, restorative stages of sleep, leading to chronic sleep disruption, persistent fatigue, and a significant impact on physical and mental well-being.
 
While two-thirds (67%) of people correctly identify sleep apnoea as interrupted breathing during sleep, one in three either misunderstand the condition or are unsure.
 
Jahangir (Jay) Ahmed is an ENT Consultant specialising in advanced sleep surgery said: “There’s no such thing as ‘simple snoring’; many of the patients I see have undiagnosed obstructive sleep apnoea, and both are highly treatable”.
 
Olivier Taelman, CEO at Nyxoah, said: “Sleep apnoea is not just snoring. Snoring might be common, but it should never be ignored, and in some cases, it could be a sign of something much more serious.”
 
Nyxoah is working to improve outcomes for people living with obstructive sleep apnoea through innovative treatment approaches, including Genio®, a next-generation therapy designed to provide an alternative option for patients who struggle with traditional treatments.
 
*Research commissioned by Nyxoah and conducted by OnePoll in 2025 among 2,000 UK adults. The survey was conducted online and weighted to be representative of the UK adult population by age, gender and region. Full methodology and dataset available on request.
 
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
 
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
 
For more information, please visit http://www.nyxoah.com/.
 
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.